Endothelin in renal diseases and cardiovascular remodeling in renal failure

Internal Medicine

Volumn 40, Issue 4, 2001, Pages 285-291

  Orth, Stephan R ^a,c   Viedt, Christiane ^a   Amann, Kerstin ^b   Ritz, Eberhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Heidelberg   (Germany)

Author keywords

End stage renal failure; Endothelin receptor; Glomerulosclerosis; Interstitial fibrosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN RECEPTOR;

ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DISEASE MODEL; DRUG ANTAGONISM; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; ENDOTHELINS; HUMANS; KIDNEY FAILURE, CHRONIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN;

EID: 0035316748     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.285     Document Type: Review

References (101)

1. Simonson MS. Endothelins: Multifunctional renal peptides. Physiol Rev 73: 375-411, 1993.
2. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098, 1998.
3. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London) 332: 411-415, 1988.
4. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327: 1774-1778, 1992.
5. Suzuki N, Matsumoto H, Miyauchi T, et al. Endothelin-3 concentrations in human plasma: the increased concentrations in patients undergoing haemodialysis. Biochem Biophys Res Commun 169: 809-815, 1990.
6. Levin ER. Endothelins. N Engl J Med 333: 356-363, 1995.
7. Hahn AWA, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1: 649-659, 1990.
8. A receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol 225: 347-350, 1992.
9. Drimal J, Mislovicova M, Ismail A, Moncek F. Detrimental subtype-specific endothelin-1 (ET-1) signaling in myocardial cells: the ET(A) mediated proliferation and ET(B) receptor down-regulation. Physiol Res 48: 9-19, 1999.
10. Kakoki M, Hirata Y, Hayakawa H, et al. Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation 99: 1242-1248, 1999.
11. Matsumura Y, Hashimoto N, Taira S, et al. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension 33: 759-765, 1999.
12. Brunner F, Doherty AM. Role of ET(B) receptors in local clearance of endothelin-1 in rat heart: studies with the antagonist PD 155080 and BQ-788. FEBS Lett 396: 238-242, 1996.
13. Modesti PA, Vanni S, Paniccia R, et al. Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes. J Cardiovasc Pharmacol 34: 333-339, 1999.
14. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 83: 708-712, 1989.
15. Jaffer FE, Knauss TC, Poptic E, Abboud HE. Endothelin stimulates PDGF secretion in cultured human mesangial cells. Kidney Int 38: 1193-1198, 1990.
16. Ishimura E, Shouji S, Nishizawa Y, Morii H, Kashgarian M. Regulation of mRNA expression for extracellular matrix (ECM) by cultured rat mesangial cells (MCs). J Am Soc Nephrol 2: 546a, 1991 (abstract).
17. Ruíz-Ortega M, Gómez-Garre D, Palacios I, et al. Effect of angiotensin II and endothelin on matrix protein synthesis by cultured mesangial cells: a complicated network of interactions. J Am Soc Nephrol 4: 664a, 1993 (abstract).
18. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 238: 249-252, 1988 (published erratum appears in FEBS Lett 244: 509, 1989).
19. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 258: C408-C415, 1990.
20. Neyses L, Nouskas J, Luyken J, et al. Induction of immediate-early genes by angiotensin II and endothelin-1 in adult rat cardiomyocytes. J Hypertens 11: 927-934, 1993.
21. Shubeita HE, McDonough PM, Harris AN, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 265: 20555-20562, 1990.
22. Benigni A. Endothelin antagonists in renal disease. Kidney Int 57: 1778-1794, 2000 (clinical conference).
23. Takagi N, Fukase M, Takata S, Yoshimi H, Tokunaga O, Fujita T. Autocrine effect of endothelin on DNA synthesis in human vascular endothelial cells. Biochem Biophys Res Commun 168: 537-543, 1990.
24. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86: 2863-2867, 1989.
25. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066-16068, 1992.
26. Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 26: 934-941, 1995.
27. Brooks DP, DePalma PD, Gellai M, et al. Nonpeptide endothelin receptor antagonists. III. Effect of SB209670 and BQ123 on acute renal failure in anesthetized dogs. J Pharmacol Exp Ther 271: 769-775, 1994.
28. Benigni A, Perico N, Gaspari F, et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 260: F331-F339, 1991.
29. Brooks DP, Contino LC, Storer B, Ohlstein EH. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 104: 987-989, 1991.
30. Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 43: 354-358, 1993.
31. Nabokov A, Amann K, Wagner J, Gehlen F, Münter K, Ritz E. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant 11: 514-520, 1996.
32. Koide H, Nakamura T, Ebihara I, Fukui M. Endothelins in diabetic kidneys. Kidney Int Suppl. 51: S45-S49, 1995.
33. B receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 50: 962-972, 1996.
34. Zoja C, Liu X-H, Abbate M, et al. Angiotensin II blockade limits tubular protein overreabsorption and the consequent up-regulation of endothelin-1 gene in experimental membranous nephropathy. Exp Nephrol 6: 121-131, 1998.
35. Nakamura T, Ebihara I, Fukui M. et al. Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Ren Physiol Biochem 16: 233-243, 1993.
36. Nakamura T, Ebihara I, Fukui M, et al. Modulation of glomerular endothelin and endothelin receptor gene expression in aminonucleoside-induced nephrosis. J Am Soc Nephrol 5: 1585-1590, 1995.
37. Niemir ZI, Chudek J, Dworacki G, et al. Primary up-regulation of the endothelin receptor type B in human glomerulonephritis (GN). Nephrol Dial Transplant 14: A14, 1999 (abstract).
38. Lehrke I, Waldherr R, Ritz E, Wagner J. Gene expression of the endothelin system in renal biopsies of proteinuric patients: effect of angiotensin converting enzyme inhibition. J Am Soc Nephrol 10: 80A, 1999 (abstract).
39. Warrens AN, Cassidy MU, Takahashi K, Ghatei MA, Bloom SR. Endothelin in renal failure. Nephrol Dial Transplant 5: 418-422, 1990.
40. Benigni A, Perico N, Gaspari F, et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 260: F331-F339, 1991.
41. A receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension 31: 995-1001, 1998.
42. Ohta K, Hirata Y, Shichiri M, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 39: 307-311, 1991.
43. Abassi ZA, Klein H, Golomb E, Keiser HR. Urinary endothelin: a possible biological marker of renal damage. Am J Hypertens 6: 1046-1054, 1993.
44. Hocher B, Paul M. Transgenic animal models for the analysis of the renal endothelin system. Nephrol Dial Transplant 15: 935-937, 2000.
45. Hocher B, Thöne-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99: 1380-1389, 1997.
46. Hocher B, Liefeldt L, Thöne-Reineke C, et al. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 28: 196-201, 1996.
47. Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44: 440-444, 1993.
48. Benigni A, Zoja C, Corna D, et al. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 27: 416-423, 1996.
49. Nakamura T, Ebihara I,Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47: 481-489, 1995.
50. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44: 895-899, 1995.
51. Watschinger B, Vychytil A, Schuller M, et al. The pathophysiologic role of endothelin in acute vascular rejection after renal transplantation. Transplantation 52: 743-746, 1991.
52. Watschinger B, Sayegh MH, Hancock WW, Russell ME. Up-regulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol 146: 1065-1072, 1995.
53. Castillo J, Berrazueta JR, Herrera L, et al. Nitric oxide and endothelins are effector agents of hyperacute vascular rejection. Transplant Proc 28: 635, 1996.
54. Forbes RD, Cernacek P, Zheng S, Gomersall M, Guttmann RD. Increased endothelin expression in a rat cardiac allograft model of chronic vascular rejection. Transplantation 61: 791-797, 1996.
55. Ravalli S, Szabolcs M, Albala A, Michler RE, Cannon PJ. Increased immunoreactive endothelin-1 in human transplant coronary artery disease. Circulation 94: 2096-2102, 1996.
56. Simonson MS, Emancipator SN, Knauss T, Hricik DE. Elevated neointimal endothelin-1 in transplantation-associated arteriosclerosis of renal allograft recipients. Kidney Int 54: 960-971, 1998.
57. A receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J Am Soc Nephrol 10: 387-391, 1999.
58. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 4: 212-224, 1997.
59. Dyadyk AI, Bagriy AE, Yarovaya NF. Left ventricular hypertrophy in chronic uremia (a review). Dial Transplant 29: 312-318, 2000.
60. Valderrabano F, Jones EH, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 10 (Suppl. 5): 1-25, 1995.
61. Agodoa LY, Eggers PW. Renal replacement therapy in the United States: data from the United States Renal Data System. Am J Kidney Dis 25: 119-133, 1995.
62. Suzuki T, Kumazaki T, Mitsui Y. Endothelin 1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun 191: 823-830, 1993.
63. Ito H, Hirata Y, Adachi S, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92: 398-403, 1993.
64. Larivière R, Deng LY, Day R, Sventek P, Thibault G, Schiffrin EL. Increased endothelin-1 gene expression in the endothelium of coronary arteries and in the endocardium of DOCA-salt hypertensive rats. J Mol Cell Cardiol 27: 2123-2131, 1995.
65. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 27: 2130-2134, 1993.
66. 2+ modulation. Circ Res 78: 302-311, 1996.
67. Molenaar P, O'Reilly G, Sharkey A, et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 72: 526-538, 1993.
68. Deng L-Y, Li J-S, Schiffrin EL. Endothelin receptor subtypes in resistance arteries from humans and rats. Cardiovasc Res 29: 532-535, 1995.
69. Peter MG, Davenpoort AP. Delineation of endothelin receptors in human left ventricular smooth-muscle cells. J Cardiovasc Pharmacol 26 (Suppl. 3): S355-S357, 1995.
70. Hori S, Komatsu Y, Shigemoto R, Mizuno N, Nakanishi S. Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology 130: 1885-1895, 1992.
71. Ito H, Hiroe M, Hirata Y, et al. Endothelin ET-A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89: 2198-2203, 1994.
72. Sakai S, Yorikane R, Miyauchi T, et al. Altered production of endothelin-1 in the hypertrophied rat heart. J Cardiovasc Pharmacol 26 (Suppl. 3): S452-S455, 1995.
73. Hasegawa K, Fujiwara H, Koshiji M, et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 27: 259-264, 1996.
74. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732-736, 1995.
75. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 89: 1580-1586, 1994.
76. Good JM, Nihoyannopoulos P, Ghatei M, et al. Elevated plasma endothelin concentrations in heart failure: an effect of angiotensin II? Eur Heart J 15: 1634-1640, 1994.
77. Yasuda M, Kohno M, Tahara A, et al. Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J 119: 801-806, 1990.
78. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384: 353-355, 1996.
79. Yazaki Y, Yamazaki T. Reversing congestive heart failure with endothelin receptor antagonists. Circulation 95: 1752-1754, 1997.
80. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation 95: 1918-1929, 1997.
81. Demuth K, Blacher J, Guerin AP, et al. Endothelin and cardiovascular remodeling in end-stage renal disease. Nephrol Dial Transplant 13: 375-383, 1998.
82. Nabokov AV, Amann K, Wessels S, Münter K, Wagner J, Ritz E. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 55: 512-519, 1999.
83. Amann K, Münter K, Wessels S, et al. Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 11: 1702-1711, 2000.
84. Brown LA, Nunez DJ, Brookes CI, Wilkins MR. Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorta-venacaval fistula rat. Cardiovasc Res 29: 768-774, 1995.
85. B receptor antagonist. Circulation 93: 2068-2079, 1996.
86. Ichikawa KI, Hidai C, Okuda C, et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol 27: 1286-1291, 1996.
87. Orth SR, Schiele G, Esslinger JP, Raschack M, Ritz E, Amann K. Effect of the endothelin A receptor antagonist LU 135252 on cardiovascular remodeling in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats (SHRsp). Hypertension (submitted): 2000.
88. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 19: 5-8, 1998.
89. 125I-labelled endothelin-1 in the kidneys: differential distribution in rat, pig and man demonstrated by using quantitative autoradiography. Clin Sci 77: 129-131, 1989.
90. Davenport AP, Morton AJ, Brown MJ. Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney. J Cardiovasc Pharmacol 17 (Suppl. 7): S152-S155, 1991.
91. 125I-endothelin-1, -2, -3 binding sites in mammalian kidneys. Comp Biochem Physiol Comp Physiol 101: 775-778, 1992.
92. B in human kidney. Kidney Int 44: 36-42, 1993.
93. 125I]endothelin-1, -2, -3 binding sites in the human kidney. Eur J Pharmacol 176: 233-236, 1990.
94. B receptors which mediate ET-1 induced cell growth. J Cardiovasc Pharmacol: 36 (Suppl. 1): S232-S237, 2000.
95. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of anti-hypertensive drugs on glomerular morphology. Kidney Int 36: 626-635, 1989.
96. Floege J, Burns MW, Alpers CE, et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297-309, 1992.
97. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 51: 2-15, 1997.
98. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
99. Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 54: 353-359, 1998.
100. Amann K, Münter K, Wagner J, et al. Treatment of cardiovascular changes in renal failure -ACE inhibition, endothelin receptor blockade or a combination of both strategies? Nephrol Dial Transplant 14 (Suppl. 4): 43-44, 1999.
101. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 57: 1675-1680, 2000.